|Dr. Michael D. Clayman M.D.||Co-Founder, Pres, CEO & Director||1.13M||N/A||1952|
|Mr. Frederick W. Driscoll||CFO & Principal Accounting Officer||N/A||N/A||1951|
|Scott Young||VP of Corp. Communications & Investor Relations||N/A||N/A||N/A|
|Ms. Carolyn Beaty Scimemi||VP, Legal Affairs & Chief Compliance Officer||N/A||N/A||N/A|
|Mr. Mark S. Levine||Gen. Counsel & Corp. Sec.||N/A||N/A||1973|
|Dr. Neil Bodick||Consultant||N/A||N/A||1947|
|Ms. Christina Willwerth||Chief Strategy Officer||N/A||N/A||1971|
|Ms. Kerry A. Wentworth||Chief Regulatory Officer||N/A||N/A||1973|
|Dr. Adam L. Muzikant Ph.D.||Chief Bus. Officer||N/A||N/A||1971|
|Ms. Melissa Layman||Chief Commercial Officer||N/A||N/A||1969|
Flexion Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of patients with musculoskeletal conditions in the United States. The company offers ZILRETTA, an intra-articular injection for the management of osteoarthritis (OA) knee pain. It is also involved in the development of FX201, a gene therapy product candidate designed to provide on demand production of an anti-inflammatory protein, interleukin-1 receptor antagonist for pain relief from OA of the knee; and FX301, a NaV1.7 inhibitor for the management of post-operative pain. The company was founded in 2007 and is headquartered in Burlington, Massachusetts.
Flexion Therapeutics, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 8. The pillar scores are Audit: 9; Board: 7; Shareholder Rights: 8; Compensation: 7.